The human coagulation factor VIII (FVIII) is an essential cofactor for the proteolytic activation of factor X. FVIII is activated by thrombin and blood coagulation factor Xa; factor IXa (FIXa) activates factor X (FXa), requiring Ca 2+ , phospholipids, and activated Factor VIII (FVIIIa) (Schmidt et al. 2005) . FVIII and von Willebrand factor (VWF) form a non-covalently bound complex. This complex (FVIII/ VWF) circulates in the human plasma, is critical to homeostasis, and normally exists in inactive form. The binding of FVIII to VWF is essential for the survival of FVIII in vivo (Kaufman and Pipe 1999). Deficiencies or structural defects in FVIII are responsible for the most common inherited bleeding disorders, such as hemophilia and von Willebrand disease (Lillicrap 2008) .
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The human coagulation factor VIII (FVIII) is an essential cofactor for the proteolytic activation of factor X. FVIII is activated by thrombin and blood coagulation factor Xa; factor IXa (FIXa) activates factor X (FXa), requiring Ca 2+ , phospholipids, and activated Factor VIII (FVIIIa) (Schmidt et al. 2005) . FVIII and von Willebrand factor (VWF) form a non-covalently bound complex. This complex (FVIII/ VWF) circulates in the human plasma, is critical to homeostasis, and normally exists in inactive form. The binding of FVIII to VWF is essential for the survival of FVIII in vivo (Kaufman and Pipe 1999) . Deficiencies or structural defects in FVIII are responsible for the most common inherited bleeding disorders, such as hemophilia and von Willebrand disease (Lillicrap 2008) .
FVIII is a polypeptide of 2332 amino acids, synthesized in the liver by parenchyma cells and hepatic sinusoidal endothelium cells, as well as by the pulmonary endothelium. FVIII has several glycosylation sites that appear to be important in its circulation kinetics. This factor possesses N-glycosydically linked glycans, which are characterized by a N-acetyl-glucosamine (GlcNAc)-asparagine inner core and are relevant for the folding and productive secretion of FVIII, and O-glycosydically glycans, which are characterized by N-acetyl-galactosamine (GalNAc)-serine/threonine and are involved in determining protein conformation and interact with other glycoproteins. FVIII possesses two unusual mannosylated sites that can be recognized by mannose receptors on Kupffer cells (Dasgupta et al. 2007 ).
FVIII binds to platelets in a saturable and specific manner (Nesheim et al. 1988; Ahmad et al. 2000) . VWF is synthesized through a multi-step process in megakaryocytic and endothelial cells, it is stored in the alpha-granule of platelets, in the Weibel-Palade body of endothelial cells, and is present in plasma and vascular subendothelium. This large protein with a unique multimeric structure plays a pivotal role in both hemostasis and pathological intravascular thrombosis as it mediates platelet adhesion to the injured vessel wall, and it carries and protects FVIII. VWF, which is composed of identical disulfide-linked 250-kDa subunits, mediates coagulation through its multiple adhesive functions for platelet membrane receptors, glycoprotein Ib-IX-V complex, integrin α IIbβ 3, heparin, various types of collagen, P-selectin (CD 62P), and FVIII, and is expressed exclusively on activated platelets (Denis 2002; Sugimoto and Miyata 2002) .
It has been suggested that the FVIII/VWF complex possesses lectin activity, since the complex interacts with amino-sugars, such as galactosamine and mannosamine, and some amino acids, such as arginine (Booth et al. 1984; Lillicrap 2008) . However, an up-to-date biological role for the FVIII/VWF complex has not been determined. A lectin is a sugar-binding protein of non-immune origin that agglutinates cells or precipitates glycoconjugates (Goldstein et al. 1980) . Lectins may be soluble or membrane-bound and occur in many types of organisms (Debray et al. 1981; Sharon and Lis 2004) . In this study, we analyzed the lectin activity and the sugar specificity of the FVIII/VWF complex, by determining hemagglutinating activity assays, its effect on platelet aggregation and its carbohydrate specificity with dextran-carbohydrate derivatives.
MATERIAL AND METHODS

Material
Fresh frozen plasma was obtained from 30 healthy donors (from the Mexican Red Cross, blood bank of the Oaxaca Delegation) for purification of the FVIII/VWF complex. Factor VIII-deficient plasma and control plasma were purchased from Behringwerke A.G., Marburg, Germany. Factor VIII was purchased from Baxter Healthcare Corporation (Deerfield, IL, USA. HEMOFIL M), N-acetylglucosamine (GlcNAc), N-acetyl-galactosamine (GalNAc), galactose, α -methyl-mannoside, streptavidin-biotin peroxidase, dextran, dimethyl sulfoxide, acrylamide, sodium dodecyl sulfate, ethylenediamine (EDTA) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
FVIII/VWF complex purification
Plasma was obtained in a trisodium citrate solution (3.2%) by adding seven parts of blood to one part of trisodium citrate; 0.1 M epsilon-N-aminocaproic acid (Sigma) was added to this solution. Complex purification was achieved in glycine-sodium chloride, pH 7.0, and then by acetone protein precipitation at 0°C (Wessel and Flugge 1984; Brodniewicz-Proba and Beauregard 1986) . Acetoneprecipitated plasma was suspended in TBS (100 mM Tris-HCl, 1 mM CaCl 2 , 0.15 M NaCl, pH 7.4). The sample of 1 ml was applied to a Concanavalin A (ConA)-Sepharose 4B (Sigma-Aldrich) column (0.6 cm × 5 cm) (Kass et al. 1969) , equilibrated with TBS. Unretained material was eluted with TBS at a flow rate of 1 ml/min until absorbance at 280 nm was below 0.001. The material retained in the column was eluted with 200 mM α -methyl-mannoside in TBS. Eluted fractions were pooled and dialyzed against TBS and kept at 4°C until used. FVIII coagulant activity was measured with activated partial thromboplastin time (aPTT) (Neothromtin, Behringwerke A.G., Marburg, Germany) (Zacharski and Rosenstein 1978) , and protein quantification was performed with the pyrogallol/molybdate complex from BioSystem S.A (Barcelona, Spain) (Yoshikazu et al. 1983) , using bovine serum albumin as standard for calibration.
Polyacrylamide gel electrophoresis
Polyacrylamide gel electrophoresis (PAGE) was performed in a slab gel apparatus with 1.5-mm spacers. Standard 5% acrylamide gels were run for 3 h in 0.05 M Tris-0.38 M glycine, pH 8.4, at 4°C, gels were stained with Coomassie blue (Butterman 1988) .
Hemagglutinating activity of the FVIII/VWF complex and sugar specificity
The hemagglutinating activity was evaluated five times using erythrocytes from different animal species, such as rabbit, goat, bovine, pig, and human, with A, B, and O blood groups. Hemagglutinating activity of the FVIII/VWF purified complex was tested by two-fold dilution in a microtiter U plate (NUC, Nunc International, Rochester, NY, USA). FVIII/VWF (1 mg/ml) was serially diluted in 25 µl PBS; finally, 25 µl of 2% erythrocyte suspension in PBS was added. These assays were performed at room temperature (23 ± 2°C), and agglutination was observed after 30-min incubation. The hemagglutinating titer (HA-titer) was reported as the inverse of the last dilution with agglutinating activity. Hemagglutination was also performed using erythrocytes previously incubated with 1 mg/ml trypsin (ICN Biomedicals Inc, CA, USA) in PBS (phosphate buffered saline, 9.5 mM phosphate, 2.7 mM potassium chloride, and 137 mM NaCl, pH 7.4) for 1 h at 37°C and washed with PBS or incubated with 0.1 U/ml Clostridium perfringens sialidase (Sigma-Aldrich) in PBS for 30 min at 37°C (Shortridge and Li-Yu 1976) . Control assays to confirm the effect of trypsin or sialidase treatment were performed using peanut agglutinin, erythrocytes were positively agglutinated after treatment, as it has been previously reported that this agglutinin is specific for galactose residues and recognizes erythrocytes only after elimination of sialidase residues or by cleavage of sialopeptides by trypsin (Pereira et al. 1976) .
Sugar specificity of FVIII/VWF was determined by comparing the effect of GlcNAc, GalNAc, galactose, and fucose on the hemagglutination induced by the complex. The complex was diluted in PBS until the hemagglutinating titer was 1:4 (four hemagglutinating doses). The diluted FVIII/VWF (25 µl) was placed in each well of the microtiter U plate and 25 µl of each monosaccharide at 200 mM were serially diluted. After 30 min incubation at room temperature, 25 µl of 2% trypsin-treated human A or B blood group or rabbit erythrocytes suspension was added. Results are expressed as the minimal sugar concentration required to inhibit four hemagglutinating doses.
Platelet aggregometry assay in the presence of FVIII/VWF and effect of carbohydrates
Blood was collected from healthy individuals with a 19-gauge needle into a syringe containing 3.8% sodium citrate and the first 2 ml were discarded. The anticoagulated blood was centrifuged at 150 g for 15 min, and the platelet-rich plasma (PRP) was removed with silicone-coated Pasteur pipettes. The PRP was maintained in plastic test tubes at room temperature for a maximum of 180 min. Platelet aggregometry with FVIII/VWF was performed by a single operator on a dual-channel platelet aggregometer (Sienco, Houston, TX, USA), based on the method of Born (Born 1964) . PRP platelet count was standardized to 200,000 platelets/µ L with autologous platelet poor plasma (obtained by centrifuging PRP at 500 g for 5 min). Incubation time was 1 min at 37°C, the stir-bar speed was 1,200 rpm and sample run time was 180 min after addition of 15 µl of 25 µM ADP (Chronolog Corporation Havertown, PA, USA). The FVIII/VWF effect was determined by adding different concentrations of the complex to ADP activated platelets. The specificity of the interaction of platelets and the complex was determined by adding FVIII/VWF previously incubated with GlcNAc, GalNAc, galactose, or fucose at different concentrations (10 to 300 mM in PBS) for 30 min at room temperature before adding 0.270 ml PRP with 200,000/ml. Results represent the mean ± standard deviation of five assays performed in triplicate.
Glycosylated-dextran derivatives assay
Biotinylated-dextran-sugar derivatives (GlcNAc, GalNAc, fucose, and galactose) were prepared as described by Hatakeyama (Hatakeyama et al. 1992 ) with modifications (Mérida et al. 1996) . Briefly, 50 mg of dextran and 50 mg of each sugar (GlcNAc, GalNAc, fucose, and galactose) were mixed and incubated with 50 µ l of divynilsulfone with 500 ppm of hydroquinone (Janssen Chemical, Geel, Belgium) in 1 ml of 0.5 M sodium carbonate, pH 11, for 18 h at room temperature. After incubation, 1 ml of 3 M ethylendiamine at pH 9.0 was added and each mixture was incubated for 8 h more at room temperature. Then, the glycosylated-dextran derivatives were dialyzed overnight against water and lyophilized. Glycosylated derivatives (5 mg) were dissolved in 1 ml of 0.1 M NaHCO 3 , plus 0.2 ml of 1.7 mg/ml hydroxysuccinimide biotin (Pierce Chemical Co., Rockford, IL, USA) in N, N-dimethylformamide (Sigma-Aldrich) and incubated for 6 h at room temperature. The samples were dialyzed against water and lyophilized.
Purified FVIII/VWF (20 µ g/ml) was coated on polystyrene microtiter plates (treated-well ELISA strips from Evergreen Scientific, CA, USA). Microtiter plates were incubated overnight at room temperature in a desiccator containing calcium chloride and concentrated sulphuric acid. The plates were kept at 4°C until used (Massó et al. 1993) . The biotinylated-dextran-sugar derivatives (1.8 to 30 µg) in 100 µl TBS-Tween (10 mM Tris-HCL, 0.15 M NaCl, 0.05% Tween 20, and 1 mM each of CaCl 2 , MgCl 2 , and MnCl 2 ) at pH 7.5 were added to the wells. After incubation for 1 h at room temperature, the solution was removed and the plates washed several times with TBSTween; then, streptavidin-HRP conjugate (100 µl) was added to each well. Finally, 100 µl of the substrate solution (0.4 mg/ml o-phenylenediamine-0.6 mg/ml H 2 O 2 in citrate-phosphate buffer, pH 5.2, compound of 24 mM citric acid and 52 mM Na 2 HPO 4 was added. The reaction was stopped after 10 min with 0.1 ml of 2.5 M H 2 SO 4 . The absorbance was measured in an ELISA reader at 490 nm (Awareness Technology, Inc., Palm City, FL, USA).
Inhibition of biotinylated-dextran-sugar derivatives was obtained by incubation with GlcNAc, fucose, GalNAc, or galactose at different concentrations (from 1 to 30 mM) that were added to the FVIII/VWF complex adsorbed to the microtiter plates (Mérida et al. 1996) . Sugar-dextran-biotin from different monosaccharides, were used as control.
Statistical analysis
Student's t test was used to compare continuous variables among groups using GraphPad Prism version 5.0 for Windows, GraphPad Software (San Diego, CA, USA).
RESULTS
Purification of the FVIII/VWF complex
FVIII/VWF purification after acetone precipitation was performed by affinity chromatography in a ConA-Sepharose 4B column, and the FVIII/VWF complex was eluted with 200 mM of α -methyl-mannoside. The purified FVIII/VWF complex consists of one band as determined by non-denaturating gel electrophoresis (data not shown).
Hemaggglutinating activity and sugar specificity of the FVIII/VWF complex
The purified FVIII/VWF complex showed hemagglutinating activity in the presence of rabbit and bovine erythrocytes at 6.0 and 12 μ g/ml concentration respectively. Erythrocytes from other animal species, such as pig and goat, as well as human A, B or O, were no agglutinated (Table 1) . After erythrocytes were treated for 30 min with trypsin or C. perfringens sialidase, the hemagglutinating activity of the complex in presence of rabbit erythrocytes increased four-times; morever, the FVIII/VWF complex showed hemagglutinaning activity in presence of human erythrocytes of blood groups A and B at concentrations of 1.5 and 3 μ g/ml, respectively; however, at similar concentrations, the goat, bovine, pig, and human O erythrocytes were not recognized even after enzyme treatment (Table 1) .
From the carbohydrates tested, only GlcNAc and fucose inhibited the hemaggglutinating activity of the complex. The minimum concentration of GlcNAc and fucose needed to inhibit four hemagglutinating doses of the FVIII/ VWF complex was 10 mM each; similar inhibitory capacity of fucose and GlcNAC was observed when hemagglutinating tests were performed in the presence of trypsinized Hemagglutinating titer (HA-titer) is reported as the inverse of the last dilution with agglutinating activity. Assays were performed using native non-treated erythrocytes and erythrocytes treated with 1 mg/ml trypsin or 0.1 U /ml C. perfringens sialidase. NA, no agglutination.
human A, B, or bovine and rabbit erythrocytes.
Platelet aggregation assay in presence of FVIII/VWF and its inhibition with carbohydrates
When the PRP (200,000 platelets/μ L) were stimulated with 15 μ l of 25 μ M ADP, 100% of cells were aggregated; when 3.5 μ g/ml FVIII/VWF complex were added, the platelet aggregation was inhibited to 40% after 6 min. When 25 mM fucose or GlcNAc were incubated previously with the FVIII/VWF complex, the aggregation reverted the inhibition to an average of 90 and 95%, respectively, whereas other carbohydrates, such as galactose and GalNAc, even at 200 mM each, reverted inhibition only to an average of 58 and 48%, respectively (P < 0.001) (Fig. 1) . As negative controls, glycine-NaCl buffer, GlcNAc, GalNAc, galactose, and fucose (all at 15 mM) were used.
FVIII/VWF binding with glycosylated-dextran derivatives assay and inhibition with carbohydrates
FVIII/VWF, at 20 μ g/ml, bound GlcNAc or fucose- Fig. 1 . Platelet aggregometry assay with FVIII/VWF. Platelet aggregation was induced with 15 μ l of 25 μ M ADP in PRP (200,000 platelets/μ l). Platelet aggregation was inhibited in the presence of 3.5 μ g/ml FVIII/VWF (X). Control assays were performed with glycine-NaCl buffer ( ). The effect of the complex was reverted by adding 25 mM GlcNAc (◊) or fucose (∆). Galactose ( ) or GalNAc ( ) showed no significant effect on the effect induced by the FVIII/VWF. Student's t test *p < 0.001. Results represent the mean ± S.D. of assays made in triplicate with platelets from five individuals. Fig. 2 . Glycosylated-dextran derivatives assay. The affinity of different monosaccharides for FVIII/VWF was evaluated by competitive assay using several carbohydrates. Purified FVIII/VWF (20 μ g/ml) was coated on polystyrene microtiter plates. The biotinylated-dextran-sugar derivatives (1.8 to 30 μ g) in 100 μ l TBS-Tween were added to the wells. The plates were washed with TBS-Tween, and Streptavidin-HRP conjugate was added to each well. The absorbance was measured in an ELISA reader at 490 nm. Fucose-dextran-biotin (control) ( ), GlcNAc ( ), fucose ( ), GalNAc (O) and galactose ( ). Student's t test *p < 0.05, † p < 0.001. The interaction of fucose-and GlcNAc-dextran derivatives was inhibited by addition of 25 mM fucose or GlcNAc monosaccharides, respectively. biotin dextran derivatives at concentrations of 1.8 μ g to 30 μ g, whereas 30 μ g of GalNAc-biotin dextran derivatives showed low interaction, and galactose-dextran derivatives showed no binding (Fig. 2) . The interaction of fucose-and GlcNAc-dextran derivatives was inhibited by adding 25 mM fucose or GlcNAc monosaccharides, respectively.
DISCUSSION
The VIII and the von Willebrand factors are plasma glycoproteins that circulate in a non-covalent complex and play a critical role in the process of blood coagulation. Most of FVIII binds to the VWF, forming a stable tight complex that protects from early proteolytic degradation and prevents its cellular uptake (Fay et al. 1991) . FVIII is an essential cofactor for activated factor IX-mediated activation of factor X. VWF mediates platelet adhesion and activation; however, no role has been attributed to the FVIII/VWF complex (Lillicrap, 2008) . In this work, we identified the potential lectin activity of the purified human plasma FVIII/VWF complex.
The ConA-purified complex FVIII/VWF showed hemagglutinating activity in the presence of bovine and rabbit erythrocytes. The purified FVIII/VWF complex showed no hemagglutinating activity in presence of human blood group erythrocytes A, B, and O. After sialidase or trypsin treatment, the recognition for bovine or rabbit erythrocytes increased four times; interestingly, human A and B type erythrocytes were recognized by the FVIII/VWF complex, and the human type O erythrocytes were not agglutinated even after enzyme treatment. The fact that FVIII/VWF has higher anti-A than anti-B specificity suggests the relevance of the carbohydrates related to blood group determinants in the interaction with the FVIII/VWF complex. Fucose and GlcNAc inhibited the hemagglutinating activity shown by the FVIII/VWF complex in the presence of any of the agglutinated erythrocytes. Galactose and GalNAc showed no effect on the hemagglutinating activity of the complex. Elimination of sialic acid or sialoglycopeptides from erythrocytes by C. perfringens or trypsin treatment, respectively, increased the agglutinating activity of the complex for rabbit and bovine erythrocytes and favored agglutination of A and B erythrocytes. This suggests that sialic acid rendered ineffective the interaction of these factors with membrane oligosaccharides and also indicates the cryptic nature of the receptor for the lectin activity. These data strongly suggest the active participation of the complex in coagulation dyscrasia associated with infections by bacterial species that produce sialidase, such as Streptococcus pneumoniae, which has been associated to the pathogenesis of the thrombotic process (Myers and Marrie 1993) .
It has been shown that VWF polymerization enhances binding affinity to platelet surface receptors GPIbα and α IIbβ 3, through electrostatic interactions (Huizinga et al. 2002; Denis et al. 2008) , suggesting that interaction with platelets is not due to interaction through lectinic receptors. From a biological point of view, the most important characteristics of the FVIII/VWF complex is to show specificity for different carbohydrates and to show certain flexibility of the binding sites that would allow for the recognition of a range of structurally related carbohydrates as a regulation mechanism similar to that of other reported lectins (Vasta et al. 1994; Hernández et al. 2004) . Vertebrate lectins fall into a number of structurally distinct families and participate in different intracellular functions, such as trafficking, sorting, and targeting of maturing glycoproteins, (Dodd and Drickamer 2001) as well as in extracellular functions, such as adhesive interactions (Zelensky and Gready 2005) , by mediating interaction with the extracellular matrix or body fluids, or by mediating cell adhesion, cell signaling, inducing gene transcription, post-translational modifications, glycoprotein clearance, and pathogen recognition (Britten et al. 1998; van Liempt et al. 2006) .
It is known that the activation of factor X to Xa is catalyzed by factor IXa and its cofactor VIIIa in the intrinsic pathway. The relevance of the functional role of carbohydrate residues in coagulation factors has been demonstrated using lectins from Galanthus nivalis agglutinin (Manspecific) (Koyama et al. 1991) , Sambucus nigra (NeuAc-α -2,6) (Sinha and Wolf 1993) , Maackia amurensis (NeuAc-α -2,3) (Sinha and Wolf 1993) , peanut (galactose), Datura stramonium (GlcNAc) (Koyama et al. 1991) , Phaseolus coccineus Var. Alubia erythroagglutinin (Pérez-Campos et al. 1997) , as well as through glycosydase treatment activating either the extrinsic or intrinsic pathways (Sinha and Wolf 1993) .
Regarding platelet aggregation in the presence of FVIII/VWF, inhibition of platelet aggregation was eliminated when carbohydrates were added to the FVIII/VWF complex. This inhibitory effect on platelet aggregation and its correction with carbohydrates has shown that the complex possesses lectin activity with better affinity for GlcNAc and fucose. On the other hand, FVIII can act as a positive regulator of platelet function in TRAP-co-stimulated platelets (Obergfell et al. 2006) , suggesting that this process is mediated by the interaction with fucosylated receptors, since it has been shown that the alpha-2-L-fucosyltransferase is highly expressed in activated platelets (Skacel and Watkins 1987) .
We propose that the FVIII/VWF complex interacts with specific oligosaccharides, which also regulate the biological role. It can be inferred that FVIII could possibly interact with fucose, from FIXa oligosaccharides, for FX activation. These carbohydrates are found in the epidermal growth factor domain of human FIXa and could interact also with carbohydrates from factor X when activated (Morita 1993) . Moreover, the possibility that the lectin activity of the FVIII/VWF induces an inhibitory effect on platelet aggregation (through GlcNAc and fucose residues) should not be ruled out.
